|
| Acute Management and Immediate Rehabilitation after Hip Fracture Amongst People Aged 65 Years and Over |
| On September 30, 2004, Vioxx (rofecoxib) was withdrawn from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information. Subsequently, on December 23, 2004, the FDA issued a public health advisory concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs) including the COX-2 selective agents Celebrex (celecoxib), Bextra (valdecoxib) and a non-selective NSAID, naproxen (sold as Aleve, Naprosyn and other trade name and generic products). See the FDA web site for more information . |
Statement Of Intent
|
Clinical guidelines are produced to help health professionals and consumers make decisions about health care in specific clinical circumstances. Research has shown that if properly developed, communicated and implemented, guidelines can improve care. The advice on acute management and immediate rehabilitation after hip fracture amongst people aged 65 years and over given in this guideline is based on epidemiological and other research evidence, supplemented where necessary by the consensus opinion of the expert development team based on their own experience.
While the guidelines represent a statement of best practice based on the latest available evidence (at the time of publishing), they are not intended to replace the health professional's judgement in each individual case. |
|
|
« Back |
|
|
